See more : BIP Bermuda Holdings I Limited (BIPI) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmatrix, Inc. (PULM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmatrix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Azure Power Global Limited (AZREF) Income Statement Analysis – Financial Results
- One World Lithium Inc. (OWLI.CN) Income Statement Analysis – Financial Results
- The NAGA Group AG (N4G.DE) Income Statement Analysis – Financial Results
- Cathedral Energy Services Ltd. (CET.TO) Income Statement Analysis – Financial Results
- Fanuc Corporation (FANUY) Income Statement Analysis – Financial Results
Pulmatrix, Inc. (PULM)
About Pulmatrix, Inc.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.30M | 6.07M | 5.17M | 12.63M | 7.91M | 153.00K | 335.00K | 835.00K | 1.20M | 352.00K | 653.00K | 0.00 |
| Cost of Revenue | 15.52M | 1.55M | 15.38M | 0.00 | 12.85M | 12.97M | 10.24M | 10.15M | 7.19M | 6.59M | 8.56M | 0.00 |
| Gross Profit | -8.22M | 4.53M | -10.21M | 12.63M | -4.94M | -12.81M | -9.91M | -9.32M | -5.99M | -6.24M | -7.91M | 0.00 |
| Gross Profit Ratio | -112.63% | 74.55% | -197.58% | 100.00% | -62.39% | -8,374.51% | -2,957.61% | -1,115.81% | -498.42% | -1,772.16% | -1,211.49% | 0.00% |
| Research & Development | 15.52M | 18.24M | 15.38M | 15.61M | 12.85M | 12.97M | 10.24M | 10.15M | 7.19M | 1.38M | 258.00K | 20.00K |
| General & Administrative | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M | 9.63M | 1.74M | 265.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.40M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M | 17.03M | 1.74M | 265.00K | 0.00 |
| Other Expenses | 0.00 | -198.00K | -11.00K | -239.00K | -205.00K | 22.00K | 0.00 | 7.53M | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 22.04M | 25.02M | 21.76M | 22.50M | 21.33M | 20.48M | 17.81M | 18.17M | 24.22M | 3.12M | 523.00K | 30.00K |
| Cost & Expenses | 22.04M | 25.02M | 21.76M | 22.50M | 21.33M | 20.48M | 17.81M | 18.17M | 24.22M | 3.12M | 523.00K | 30.00K |
| Interest Income | 867.00K | 309.00K | 7.00K | 82.00K | 301.00K | 27.00K | 0.00 | 0.00 | 17.00K | 17.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00K | 643.00K | 881.00K | 953.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.48M | 1.55M | 1.24M | 1.04M | 765.00K | 231.00K | 246.00K | 250.00K | 232.00K | 2.00K | 352.00K | 0.00 |
| EBITDA | -13.27M | -17.40M | -15.35M | -9.86M | -13.24M | -20.15M | -17.17M | -29.67M | -25.21M | -3.12M | -3.12M | -30.00K |
| EBITDA Ratio | -181.76% | -312.09% | -251.75% | 3.72% | -158.82% | -13,122.88% | -5,142.99% | -2,045.75% | -1,897.25% | -885.23% | -80.09% | 0.00% |
| Operating Income | -14.74M | -18.95M | -20.17M | -573.00K | -20.69M | -20.33M | -17.48M | -24.87M | -23.02M | -3.12M | -523.00K | -30.00K |
| Operating Income Ratio | -201.97% | -312.09% | -390.15% | -4.54% | -261.59% | -13,288.24% | -5,216.42% | -2,977.96% | -1,916.57% | -885.80% | -80.09% | 0.00% |
| Total Other Income/Expenses | 619.00K | 111.00K | -4.00K | -9.45M | 96.00K | -232.00K | -581.00K | -5.94M | -3.15M | -17.44M | 5.32M | 0.00 |
| Income Before Tax | -14.12M | -18.84M | -20.17M | -19.31M | -20.60M | -20.56M | -18.06M | -30.80M | -26.17M | -3.12M | -523.00K | -30.00K |
| Income Before Tax Ratio | -193.49% | -310.26% | -390.23% | -152.83% | -260.38% | -13,439.87% | -5,389.85% | -3,688.86% | -2,178.77% | -885.80% | -80.09% | 0.00% |
| Income Tax Expense | 0.00 | -111.00K | 2.33M | 9.21M | -205.00K | 68.00K | -62.00K | -2.96M | 2.20M | -15.07M | -2.60M | 0.00 |
| Net Income | -14.12M | -18.73M | -22.51M | -28.52M | -20.39M | -20.56M | -18.06M | -27.84M | -26.17M | -3.12M | -523.00K | -30.00K |
| Net Income Ratio | -193.49% | -308.43% | -435.38% | -225.70% | -257.79% | -13,439.87% | -5,389.85% | -3,334.49% | -2,178.77% | -885.80% | -80.09% | 0.00% |
| EPS | -3.87 | -5.43 | -8.31 | -19.83 | -24.37 | -99.67 | -186.42 | -375.87 | -646.91 | -765.72 | -130.75 | -0.18 |
| EPS Diluted | -3.87 | -5.43 | -8.31 | -19.83 | -24.37 | -99.67 | -186.42 | -375.87 | -646.91 | -765.72 | -130.75 | -0.18 |
| Weighted Avg Shares Out | 3.65M | 3.45M | 2.71M | 1.44M | 836.70K | 206.32K | 96.86K | 74.08K | 40.45K | 4.07K | 4.00K | 170.00K |
| Weighted Avg Shares Out (Dil) | 3.65M | 3.45M | 2.71M | 1.44M | 836.70K | 206.32K | 96.86K | 74.08K | 40.45K | 4.07K | 4.00K | 170.00K |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM
PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders
Pulmatrix and Cullgen Announce Proposed Merger
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Source: https://incomestatements.info
Category: Stock Reports